Online citations, reference lists, and bibliographies.
← Back to Search

N-(1,2-diphenylethyl)piperazines: A New Class Of Dual Serotonin/noradrenaline Reuptake Inhibitor.

M. Jonathan Fray, G. Bish, A. Brown, P. V. Fish, A. Stobie, Florian Wakenhut, G. Whitlock
Published 2006 · Medicine, Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The synthesis and structure-activity relationships of a novel series of piperazine derivatives as dual inhibitors of serotonin and noradrenaline reuptake is described. Two compounds possessed comparable in vitro profiles to the dual reuptake inhibitor duloxetine.
This paper references
10.1016/S0029-7844(03)00376-4
Mixed Urinary Incontinence Symptoms: Urodynamic Findings, Incontinence Severity, and Treatment Response
R. Bump (2003)
10.1248/CPB.47.1790
Roles of two basic nitrogen atoms in 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives in production of opioid agonist and antagonist activities.
K. Natsuka (1999)
Psychopharmacology: The Fourth Generation of Progress
F. Bloom (1995)
10.1021/JO00885A032
A simple method for converting nitriles to amides. Hydrolysis with potassium hydroxide in tert-butyl alcohol
J. H. Hall (1976)
Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents.
S. Dubovsky (1994)
New indications for antidepressants.
A. Schatzberg (2000)
10.1124/jpet.104.075960
Efficacy of Duloxetine, a Potent and Balanced Serotonergic and Noradrenergic Reuptake Inhibitor, in Inflammatory and Acute Pain Models in Rodents
C. Jones (2005)
10.1034/j.1600-0447.2000.02604.x
Brain noradrenaline and the mechanisms of action of antidepressant drugs
T. Svensson (2000)
10.1177/106002809402801207
Selective Serotonin Reuptake Inhibitors: Pharmacologic Profiles and Potential Therapeutic Distinctions
P. Finley (1994)
10.1021/JM00210A017
Studies on 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives and their analgesic activities. 2. Structure-activity relationships of 1-cycloalkyl-4-(1,2-diphenylethyl)piperazines.
K. Natsuka (1978)
10.1021/JM0582423
Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.
S. Kotturi (2005)
10.1034/j.1600-0447.2000.02606.x
Reboxetine: tolerability and safety profile in patients with major depression
L. Tanum (2000)
10.1002/(SICI)1099-1077(199802)13:1+3.0.CO;2-6
Rationale for the development of noradrenaline reuptake inhibitors
N. Brunello (1998)
10.1111/J.1527-3458.2002.TB00234.X
Duloxetine pharmacology: profile of a dual monoamine modulator.
K. Karpa (2002)
10.1039/P19890000225
The chemistry of N-substituted benzotriazoles. Part 14. Novel routes to secondary and tertiary amines and to N, N-disubstituted hydroxylamines
A. R. Katritzky (1989)
10.1016/J.BMCL.2004.08.005
Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake.
J. Boot (2004)
Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
A. Schatzberg (2003)
10.1016/S0040-4020(98)00353-6
The preparation of functionalized amines and amides using benzotriazole derivatives and organozinc reagents
A. Katritzky (1998)
10.1002/HUP.620
Serotonin and noradrenaline reuptake inhibitors in animal models of pain
Daisuke Mochizucki (2004)
10.1016/J.BMCL.2003.08.079
Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.
F. Bymaster (2003)
10.1176/APPI.PSY.45.1.17
Effects of duloxetine on painful physical symptoms associated with depression.
D. Goldstein (2004)
10.1039/JR9620001420
269. The chemotherapy of amœbiasis. Some N-substituted dichloroacetamides
D. Kidd (1962)
10.1038/sj.mp.4000728
Neurotransmitter transporters: fruitful targets for CNS drug discovery
L. Iversen (2000)
10.2174/0929867013373796
Current trends in the development of new antidepressants.
P. Pacher (2001)
10.1093/HRP/7.2.69
Selective serotonin-reuptake inhibitors: an update.
P. Masand (1999)
10.1111/J.1527-3458.2003.TB00258.X
The promises and pitfalls of reboxetine.
M. Page (2003)
10.1016/S0022-3956(02)00060-2
Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
M. Detke (2002)



This paper is referenced by
Targeted histone deacetylase inhibition
William Guerrant (2012)
Interaction of small molecules with nucleic acid targets: From RNA secondary structure to the ribosome
Joshua C. Canzoneri (2012)
10.1021/jm200799p
Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
William Guerrant (2012)
10.1016/j.bmcl.2008.03.050
Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.
P. V. Fish (2008)
10.1016/j.bmcl.2009.07.049
N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration.
Florian Wakenhut (2009)
10.1093/jat/bkv006
First reported fatalities associated with the 'research chemical' 2-methoxydiphenidine.
S. Elliott (2015)
10.1016/J.BMCL.2007.01.020
N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors.
P. V. Fish (2007)
10.1002/dta.1800
Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta- and para-substituted isomers.
G. McLaughlin (2016)
10.1016/J.TET.2007.02.086
Straightforward three-component synthesis of diarylmethylpiperazines and 1,2-diarylethylpiperazines
S. Sengmany (2007)
10.1016/j.bmcl.2008.02.036
[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors.
P. V. Fish (2008)
10.3390/molecules25071497
Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors
R. Martinez (2020)
10.1517/13543776.17.8.889
Enhanced selective serotonin re-uptake inhibitors as antidepressants: 2004 – 2006
Y. Huang (2007)
10.1039/C6RA09717K
Design and synthesis of novel dual-target agents for HDAC1 and CK2 inhibition
M. Purwin (2016)
10.4103/0975-7406.80765
Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review
N. Siddiqui (2011)
10.1007/7355_2008_028
Design of monoamine reuptake inhibitors: SSRIs, SNRIs and NRIs
G. Whitlock (2008)
10.1016/j.bmcl.2008.06.078
N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.
Florian Wakenhut (2008)
10.1016/j.bmcl.2008.03.082
Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.
G. Whitlock (2008)
10.1016/j.bmcl.2008.06.071
Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.
P. V. Fish (2008)
10.1016/j.bmcl.2009.03.090
4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: design, synthesis and structure-activity relationships.
P. V. Fish (2009)
10.1016/j.bmcl.2010.04.052
Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.
M. Fray (2010)
10.1007/164_2018_148
1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances.
J. Wallach (2018)
10.1016/J.BMCL.2007.11.080
1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.
G. Whitlock (2008)
10.1039/c8cc03764g
Diastereoselective addition of anisoles to N-tert-butanesulfinyl imines via four-membered lithium cycles.
L. R. Reddy (2018)
10.1371/journal.pone.0157021
Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues
J. Wallach (2016)
Semantic Scholar Logo Some data provided by SemanticScholar